Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Rationale:
Standard therapy for anaplastic oligodendrogliomas and mixed oligoastrocytomas includes
radiation and chemotherapy. However, due to the potential long-term central nervous system
toxicity from radiation, researchers speculate that it may be better to reserve radiation
therapy for progressive disease. In addition, some patients with anaplastic oligodendroglioma
and mixed oligoastrocytoma have unusually chemosensitive tumors. Previous research indicates
that brain tumor patients with a deletion of the 1p chromosome have a higher response to the
chemotherapy drug temozolomide.